FibroGen to Report Second Quarter 2025 Financial Results
FibroGen (NASDAQ: FGEN) has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025, after market close. The company will host a conference call and webcast presentation at 5:00 PM Eastern Time on the same day.
The event will feature the FibroGen management team presenting financial results and providing a business update, followed by a live Q&A session. Investors can access the audio webcast through the company's website, and dial-in details will be provided upon registration.
FibroGen (NASDAQ: FGEN) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per lunedì 11 agosto 2025, dopo la chiusura del mercato. La società terrà una conference call e una presentazione in webcast alle 17:00 ora della costa orientale degli Stati Uniti dello stesso giorno.
L'evento vedrà il team di gestione di FibroGen presentare i risultati finanziari e fornire un aggiornamento sull'attività, seguito da una sessione di domande e risposte in diretta. Gli investitori potranno accedere all'audio webcast tramite il sito web dell'azienda, con i dettagli per la chiamata forniti al momento della registrazione.
FibroGen (NASDAQ: FGEN) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el lunes 11 de agosto de 2025, después del cierre del mercado. La compañía realizará una llamada de conferencia y una presentación en webcast a las 5:00 PM hora del Este del mismo día.
El evento contará con la participación del equipo directivo de FibroGen, que presentará los resultados financieros y proporcionará una actualización del negocio, seguido de una sesión de preguntas y respuestas en vivo. Los inversores podrán acceder a la transmisión de audio a través del sitio web de la empresa, y se proporcionarán los detalles para la llamada tras la inscripción.
FibroGen (NASDAQ: FGEN)은 2025년 2분기 재무 결과 발표를 2025년 8월 11일 월요일 장 마감 후에 예정했습니다. 회사는 같은 날 동부 표준시 오후 5시에 컨퍼런스 콜과 웹캐스트 프레젠테이션을 진행할 예정입니다.
이번 행사에서는 FibroGen 경영진이 재무 결과를 발표하고 사업 현황을 업데이트하며, 이후 실시간 질의응답 세션이 이어집니다. 투자자들은 회사 웹사이트를 통해 오디오 웹캐스트에 접속할 수 있으며, 등록 시 전화 접속 정보가 제공됩니다.
FibroGen (NASDAQ : FGEN) a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le lundi 11 août 2025, après la clôture des marchés. La société organisera une conférence téléphonique et une présentation en webcast à 17h00 heure de l'Est le même jour.
L'événement comprendra une présentation des résultats financiers et une mise à jour commerciale par l'équipe de direction de FibroGen, suivie d'une session de questions-réponses en direct. Les investisseurs pourront accéder à la diffusion audio via le site web de l'entreprise, avec les détails d'accès fournis lors de l'inscription.
FibroGen (NASDAQ: FGEN) hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für Montag, den 11. August 2025, nach Börsenschluss, angekündigt. Das Unternehmen wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz und eine Webcast-Präsentation abhalten.
Die Veranstaltung beinhaltet eine Präsentation der Finanzergebnisse und ein Geschäftsupdate durch das Management von FibroGen, gefolgt von einer Live-Fragerunde. Investoren können den Audio-Webcast über die Webseite des Unternehmens verfolgen; die Einwahldaten werden nach der Registrierung bereitgestellt.
- None.
- None.
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation
The FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on FibroGen’s website.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@fibrogen.com
FAQ
When will FibroGen (FGEN) report Q2 2025 earnings?
What time is FibroGen's Q2 2025 earnings call?
How can investors access FibroGen's Q2 2025 earnings call?
Will there be a replay available of FibroGen's Q2 2025 earnings call?
